The National Institutes of Health announced Wednesday that it has begun a clinical trial to determine the risk of allergic reactions to Moderna’s and Pfizer’s COVID-19 vaccines.
Investigators will look into whether allergic reactions are more frequent in people who are “highly allergic or have a mast cell disorder” than in people who do not have allergies, according to a news release from NIH.
The study will also investigate the “biological mechanism” behind systemic allergic reactions to better understand what factors put someone at more risk.
“The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement.
“The information gathered during this trial will help doctors advise people who are highly allergic or have a mast cell disorder about the risks and benefits of receiving